| Literature DB >> 28472172 |
Gil Levy1, Yoav Peled2, Anat From2, Irena Fainberg1, Sarit Barak1, Amir Aviram2, Haim Krissi2.
Abstract
We aimed to compare the long-term surgical outcome and complications of multiparous and grand multiparous women undergoing reconstructive surgery with vaginal mesh implants for repair of pelvic organ prolapse. This retrospective, long-term follow-up (28.17±20.7 months) comprised 113 women who underwent surgical reconstructive surgery with vaginal polypropylene mesh in a high parity rate population medical center. The women were divided into 2 groups (multiparous and grand multiparous) and each group was evaluated for objective and subjective surgical outcome. Patient demographics and surgical data were retrieved from electronic medical records. Outcome measure included POP-Q exam as objective outcome and validated Pelvic Floor Distress Inventory questionnaire (PFDI) to assess subjective outcome. Average age of patients was 62±7.9 (range 42-83) years. Average parity was 5.6±3.1 (range 1-14). There were 54 (47.7%) multiparous women and 59 (52.3%) grand multiparous women. The grand multiparous women were younger than the multiparous women and had a significantly higher degree of prolapse. At the last follow-up, the only significant difference was related to symptoms of an overactive bladder. In conclusion, long-term follow-up demonstrates that vaginal mesh surgery in grand multiparous women offers anatomical and subjective cure rates comparable to multiparous women.Entities:
Mesh:
Year: 2017 PMID: 28472172 PMCID: PMC5417596 DOI: 10.1371/journal.pone.0176666
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
POP-Q* for the whole group before and after the procedure and by group prior to surgery.
| Variable | Before Median (range) | After Median (range) | ||
|---|---|---|---|---|
| Aa | 3.0 (-3 - +3) | -3.0 (-3 - +3) | ||
| Ba | 3.0 (-3 - +8) | -3.0 (-3 - +6) | ||
| C | 1.0 (-8 - +8) | -7.0 (-9 - +6) | ||
| GH | 5.0 (2–8) | 4.5 (3–7) | ||
| PB | 2.0 (2–5) | 3.0 (2–5) | ||
| TVL | 8.0 (6–10) | 8.0 (6–9) | ||
| Ap | -1.0 (-3 - +3) | -3.0 (-3 - +3) | ||
| Bp | -1.0 (-3 - +8) | -3.0 (-3 - +6) | ||
| D | -4.0 (-8 - +8) | -7.0 (-9 - +6) | ||
| GM | M | p value | ||
| Aa | 3.0 (-3 - +3) | 2.5 (-3 - +3) | ||
| Ba | 4.0 (-3 - +8) | 2.5 (-3 - +8) | ||
| C | 1.0 (-8 - +8) | -0.5 (-8 - +8) | ||
| GH | 6.0 (2–7) | 4.0 (2–8) | ||
| PB | 2.0 (2–3) | 2.0 (2–5) | ||
| TVL | 8.0 (7–10) | 8.0 (6–9) | 0.07 | |
| Ap | -1.0 (-3 - +3) | -1.0 (-3 - +3) | 0.09 | |
| Bp | 0.0 (-3 - +8) | -1.0 (-3 - +8) | ||
| D | -3.0 (-8–8) | -5.0 (-7 - +8) | ||
* Bump RC et al. [11].
Ba, maximum descent of anterior vaginal wall; Bp, maximum descent of posterior vaginal wall; C, maximum descent of the cervix or vaginal cuff; POP-Q, pelvic organ prolapse quantification; TVL, total vaginal length
Patient's characteristics.
| Variable | GM group (n = 59) | M group (n = 54) | |
|---|---|---|---|
| Age (years), mean±SD | 60.4±7.0 | 63.7±8.6 | |
| Body mass index (kg/m2), mean±SD | 27.2±4.8 | 27.3±3.3 | 0.89 |
| Gravidity, median (range) | 8.0 (5–14) | 3.0 (1–4) | |
| Previous Cesarean Delivery, n (%) | 10 (17.2) | 2 (3.7) | 0.02 |
| Previous Operative Vaginal Delivery, n (%) | 5 (8.5) | 6 (11.1) | 0.64 |
| Previous prolapse procedure, n (%) | 0 (0) | 1 (1.0) | 0.80 |
| Fecal incontinence, n (%) | 1 (1.7) | 2 (3.7) | 0.51 |
| Constipation, n (%) | 7 (11.9) | 6 (11.1) | 0.90 |
| Hormone replacement therapy, n (%) | 0 (0) | 2 (3.7) | 0.14 |
| Previous hysterectomy, n (%) | 5 (8.5) | 10 (18.5) | 0.12 |
| Diabetes mellitus, n (%) | 5 (8.5) | 5 (9.3) | 0.88 |
| Chronic hypertension, n (%) | 12 (20.7) | 13 (24.1) | 0.67 |
| Smoking, n (%) | 1 (1.7) | 2 (3.7) | 0.51 |
GM, grand multipara; M, multipara; POP-Q, pelvic organ prolapse quantification
All values presented are means±SD or number (%).
Surgical procedures.
| Variable, n(%) | GM group (n = 59) | M group (n = 54) | |
|---|---|---|---|
| SSLF | 26 (44.1) | 7 (13.0) | <0.001 |
| TVTO | 29 (49.2) | 22 (40.7) | 0.37 |
| SI TVT | 7 (11.9) | 3 (5.6) | 0.24 |
| SI general | 36 (61.0) | 25 (46.3) | 0.12 |
| Vaginal hysterectomy | 24 (40.7) | 12 (22.2) | 0.04 |
| Post mesh GAC | 2 (3.4) | 1 (1.9) | 0.61 |
| Post mesh Endofast | 1 (1.7) | 0 (0) | 0.34 |
| Post mesh Elevate | 1 (1.7) | 0 (0) | 0.34 |
| Post mesh prolift | 6 (10.2) | 10 (18.5) | 0.20 |
| Post mesh General | 10 (16.9) | 11 (20.4) | 0.64 |
| Ant. mesh GAC | 2 (3.4) | 0 (0) | 0.17 |
| Ant. mesh Endofast | 1 (1.7) | 0 (0) | 0.34 |
| Ant. mesh Elevate | 3 (5.1) | 3 (5.6) | 0.91 |
| Ant. mesh prolift | 45 (76.3) | 40 (74.1) | 0.79 |
| Ant. mesh General | 51 (86.4) | 43 (79.6) | 0.33 |
GM, grand multipara; M, multipara
SSLF = sacrospinous ligament fixation, TVTO® = Johnson and Johnson product, TVT® = Johnson and Johnson product, GAC = Graft augmented colporrhaphy using self-cut Gynamesh® anchored proximally to the SSLF bilaterally using prolene sutures and distally to the para-urethral tissue bilaterally. Elevate®—AMS product, Prolift®—Johnson and Johnson product, Endofast®–IBI product. General = summary of all mesh procedures per compartment.
Follow-up results.
| Variable | GM group (n = 59) | M group (n = 54) | |
|---|---|---|---|
| Follow-up duration (month) | 35.0 (37.0) | 22.5 (36.0) | 0.3 |
| POP-Q | |||
| Aa | -3.0 (-3 - +3) | -3.0 (-3 - +3) | 0.57 |
| Ba | -3.0 (-3 - +6) | -3.0 (-3 - +2) | 0.13 |
| C | -7.0 (-9 - +6) | -7.0 (-9 - +3) | 0.15 |
| GH | 5.0 (3–7) | 4.0 (3–5) | 0.12 |
| PB | 3.0 (2–4) | 3.0 (2–5) | 0.55 |
| TVL | 8.0 (6–9) | 8.0 (6–9) | 0.84 |
| Ap | -3.0 (-3 - +3) | -3.0 (-3 - +3) | 0.96 |
| Bp | -3.0 (-3 - +6) | -3.0 (-3 - +4) | 0.44 |
| D | -7.0 (-9 - +6) | -7.0 (-8 - +6) | 0.41 |
| PFDI | 15.0 (0–56) | 17.0 (0–47) | 0.65 |
| Postoperative complications/additional surgery | |||
| Local estrogen treatment | 2 (3.4) | 2 (3.7) | 0.93 |
| Posterior repair | 1 (1.7) | 0 (0) | 0.34 |
| Erosion remove | 2 (3.3) | 1 (1.9) | 0.29 |
| Additional Sacrocolpopexy | 2 (3.4) | 0 (0) | 0.17 |
| Vaginal hysterectomy and posterior and anterior colporrhaphy | 6 (10.2) | 3 (5.6) | 0.37 |
| Stress urinary incontinence | 2 (3.4) | 2 (3.7) | 0.93 |
| Voiding difficulty | 0 (0) | 1 (1.9) | 0.29 |
| Overactive bladder | 23 (39.0) | 9 (16.7) | 0.009 |
| Fecal symptoms | 1 (1.7) | 2 (3.7) | 0.51 |
| Chronic pelvic pain/dyspareunia | 3 (5.1) | 2 (3.7) | 0.72 |
| Recurrent posterior wall prolapse | 2 (3.4) | 1 (1.9) | 0.61 |
| Recurrent vault prolapse | 2 (3.4) | 0 (0) | 0.17 |
| Recurrent Uterine prolapse | 7 (11.9) | 4 (7.4) | 0.43 |
| Recurrence of any site prolapse | 11 (18.6) | 5 (9.3) | 0.15 |
| Urinary tract infection | 1 (1.7) | 0 (0) | 0.34 |
| Local infection | 3 (5.1) | 4 (7.4) | 0.34 |
| Dyspareunia | 5 (8.5) | 8(14.8) | 0.29 |
| Mesh exposure | 8 (13.6) | 11 (20.4) | 0.33 |
| Bleeding (>500ml) | 3 (5.1) | 0 (0) | 0.09 |
| Hematoma | 0 (0) | 0 (0) | NA |
* Bump RC et al. [11].
GM, grand multipara; M, multipara; PFDI, Pelvic Floor Distress Inventory
POP Q* for multiparous women before and after the procedure.
| POP Q | M group (n = 54) | ||
|---|---|---|---|
| Variable | Before | After | |
| Aa | 2.5 (-3 - +3) | -3.0 (-3 - +3) | <0.001 |
| Ba | 2.5 (-3 - +8) | -3.0 (-3 - +2) | <0.001 |
| C | -0.5 (-8 - +8) | -7.0 (-9 - +3) | <0.001 |
| GH | 4.0 (2–8) | 4.0 (3–5) | 0.03 |
| PB | 2.0 (2–5) | 3.0 (2–5) | 0.05 |
| TVL | 8.0 (6–9) | 8.0 (6–9) | 0.02 |
| Ap | -1.0 (-3 - +3) | -3.0 (-3 - +3) | <0.001 |
| Bp | -1.0 (-3 - +8) | -3.0 (-3 - +4) | <0.001 |
| D | -5.0 (-7 - +8) | -7.0 (-8 - +6) | 0.01 |
* Bump RC et al. [11].
M, multipara;
POP Q* for grand multiparous women, before and after the procedure.
| GM group (n = 59) | ||
|---|---|---|
| Variable | Before | After |
| Aa | 3.0 (-3 - +3) | -3.0 (-3 - +3) |
| Ba | 4.0 (-3 - +8) | -3.0 (-3 - +6) |
| C | 1.0 (-8 - +8) | -7.0 (-9 - +6) |
| GH | 6.0 (2–7) | 5.0 (3–7) |
| PB | 2.0 (2–3) | 3.0 (2–4) |
| TVL | 8.0 (7–10) | 8.0 (6–9) |
| Ap | -1.0 (-3 - +3) | -3.0 (-3 - +3) |
| Bp | 0.0 (-3 - +8) | -3.0 (-3 - +6) |
| D | -3.0 (-8 - +8) | -7.0 (-9 - +6) |
* Bump RC et al. [11].
GM, Grandmultipara;
Improvement of POP Q*, by parity.
| Variable | GM (n = 59) | M group (n = 54) | |
|---|---|---|---|
| Aa | -5.0 (-6 - +6) | -5.0 (-6 - +6) | 0.22 |
| Ba | -5.0 (-11 - +5) | -5.0 (-11 - +5) | 0.22 |
| C | -6.5 (-16 - +5) | -5.0 (-14 - +8) | 0.42 |
| GH | -1.0 (-3 - +1) | 0.0 (-3 - +2) | 0.03 |
| PB | 1.0 (0–2) | 0.0 (-2 - +3) | 0.05 |
| TVL | -1.0 (-3 - +1) | 0.0 (-3 - +3) | 0.14 |
| Ap | -2.0 (-6 - +5) | -1.0 (-6 - +3) | 0.15 |
| Bp | -2.0 (-11 - +3) | -1.0 (-9 - +4) | 0.09 |
| D | -2.5 (-16 - +1) | -2.0 (-4 - +1) | 0.19 |
* Bump RC et al. [11].
GM, grand multipara; M, multipara